Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01311661 · ClinicalTrials.gov registry record · Phase 2
A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 206
- Enrollment target
NCT01311661 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 206 participants.
The verdict
NCT01311661, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 206 participants
- Enrollment target
Study Summary
This study will compare efficacy and safety of different regimens of olodaterol administration in asthma (once daily, twice daily) with placebo in a complete cross-over design each within one of the two daily dose groups (medium or high daily dose).
Interventions
- DRUG Placebo twice daily
- DRUG Olodaterol low daily dose twice daily
- DRUG Olodaterol medium daily dose twice daily
- DRUG Olodaterol high daily dose once daily and placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01311661
The ClinicalTrials.gov registry entry for NCT01311661 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo twice daily is the first listed.
NCT01311661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01311661 about?
NCT01311661 is a clinical study titled "A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma". This study will compare efficacy and safety of different regimens of olodaterol administration in asthma (once daily, twice daily) with placebo in a complete cross-over design each within one of the two daily dose groups (medium or high daily dose).
What is the current status of trial NCT01311661?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 206 participants. The study started on 2011-03.
What interventions are being tested in trial NCT01311661?
The interventions under investigation include: Placebo twice daily (DRUG), Olodaterol low daily dose twice daily (DRUG), Olodaterol medium daily dose twice daily (DRUG), Olodaterol high daily dose once daily and placebo (DRUG).
Who is sponsoring clinical trial NCT01311661?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.